Fibrotic scarring is a major challenge in recovery post spinal cord injury (SCI). Researchers reveal that transforming growth factor- β1 (TGF- β1) signaling promotes scar tissue formation by encouraging fibroblast development from MSCs and pericytes. Using a mouse model, Dr. Dayu Pan and his team of researchers reveal that limiting macrophage-derived TGF-β1 reduced scar formation and improved recovery, suggesting that targeting abnormal TGF- β1 activation may aid in recovery after SCI.

This review examines the gut–brain axis (GBA) as a critical bidirectional network linking gut microbiota to brain function and pathology. It details key pathways—neural, immune, endocrine, and metabolic—through which gut-derived signals influence conditions like depression, Alzheimer’s, and Parkinson’s disease. The article highlights novel microbiota-targeted therapies, including probiotics, fecal transplantation, and dietary strategies, underscoring their potential for pioneering personalized approaches in neuropsychiatry. These hold promises for innovative treatments. Personalized medicine is the way forward.

Animal studies often fail to predict human tissue responses to new drugs or newly developed therapies. Besides generating tremendous costs for clinical studies, it also raises significant ethical concerns. Therefore, novel approaches in mimicking natural human environments like vascular system growth control, are broadly developed to deliver a reproducible model to test novel drugs. Recently, researchers from the Institute of Physical Chemistry demonstrated a unique system that is based on endothelial cells coated onto the surface of microparticles that can be spatially organized into pre-designed patterns to initiate the growth of vascular systems of well-defined micro-architecture. The patterning is achieved via directed-assembly using external magnetic fields. The discovery opens up new opportunities for personalized drug testing and precision medicine. Let’s take a cool closer on this breakthrough.